In last trading session, Adma Biologics Inc (NASDAQ:ADMA) saw 2.86 million shares changing hands with its beta currently measuring 0.45. Company’s recent per share price level of $6.29 trading at $0.1 or 1.62% at ring of the bell on the day assigns it a market valuation of $1.44B. That closing price of ADMA’s stock is at a discount of -2.38% from its 52-week high price of $6.44 and is indicating a premium of 52.46% from its 52-week low price of $2.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.79 million shares which gives us an average trading volume of 2.71 million if we extend that period to 3-months.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Upright in the green during last session for gaining 1.62%, in the last five days ADMA remained trading in the green while hitting it’s week-highest on Friday, 03/22/24 when the stock touched $6.29 price level, adding 2.78% to its value on the day. Adma Biologics Inc’s shares saw a change of 39.16% in year-to-date performance and have moved 5.01% in past 5-day. Adma Biologics Inc (NASDAQ:ADMA) showed a performance of 19.58% in past 30-days. Number of shares sold short was 6.72 million shares which calculate 3.05 days to cover the short interests.
Adma Biologics Inc (ADMA) estimates and forecasts
The company is estimating its revenue growth to increase by 266.70% in the current quarter and calculating 333.30% increase in the next quarter. This year revenue growth is estimated to rise 29.30% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $77.27 million for the same. And 4 analysts are in estimates of company making revenue of $81.27 million in the next quarter that will end on Jun 2024. Company posted $56.91 million and $60.12 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 35.80% while estimating it to be 35.20% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.68% during past 5 years.
ADMA Dividends
Adma Biologics Inc is more likely to be releasing its next quarterly report between May 08 and May 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders are in possession of 2.50% of company’s total shares while institution are holding 77.24 percent of that, with stock having share float percentage of 79.22%. Investors also watch the number of corporate investors in a company very closely, which is 77.24% institutions for Adma Biologics Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at ADMA for having 17.92 million shares of worth $112.7 million. And as of Dec 30, 2023, it was holding 7.85% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 12.89 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 5.65% of outstanding shares, having a total worth of $81.09 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 6.41 million shares of worth $40.33 million or 2.81% of the total outstanding shares. The later fund manager was in possession of 5.12 million shares on Jan 30, 2024, making its stake of worth around $32.2 million in the company or a holder of 2.24% of company’s stock.
